must be integrated with biology and medicine. Major advancements can only be achieved as a result of collaborative efforts with partners from a range of disciplines that provide a wide spectrum of different kinds of expertise. To stimulate this, in 2016 the European Society of Artificial organs (ESAO), established a new working group on "Bioartificial organs." The group includes experts from all these disciplines and focuses on organizing symposia at various international conferences, training events for young researchers entering the field, as well as outreach activities to promote the field to a broad audience (see). This special issue also aims to highlight some important, recent developments in the field by bringing together some significant contributions. Summary of contents Bioartificial organs This issue contains two important contributions on bioartificial organs: one study on a bioartificial liver and one on a pancreas. Figaro et al focus on optimizing the fluidized bed bioreactor as an external bioartificial liver (15). The team had previously designed and validated a new bioartificial liver (BAL) based on a Prismaflex™ device, including fluidized bed bioreactors hosting alginate-encapsulated hepatocytes. In this contribution, they assess the impact of the bead production process, the bed fluidization, mass transfer and the bead mechanical properties on the cell viability and basic metabolic function. Based on their results, and the constraints of all the extracorporeal circulation (plasma flow rate, thermal exchange), a concentration of 2 mg (1% v/v) of microspheres for 15-20 million cells per milliliter of alginate solution appears to be the best configuration. The filling ratio for the beads in the bioreactors could reach 60%. Four 250-mL bioreactors represent approximately 15% of the hepatocytes in a liver, which is a reasonable target for extracorporeal liver supply. Long et al focus on co-microencapsulation of bone marrow mesenchymal stem cells and mouse pancreatic β cells to treat diabetic mice (16). They found out that after 28 days of in vitro culture, the secretion of insulin following comicroencapsulation is higher than that observed for microencapsulated beta-TC-6 cells alone. On the 28 th day after transplantation, the blood glucose level reach 6.86 mmol/L in the microencapsulated beta-TC-6 group. On the 14 th day, the blood glucose level was 6.80 mmol/L in the co-microencapsulated BMSC/beta-TC-6 group, which is close to the normal blood glucose level of healthy mice. Their study indicates that combining microencapsulation technology and co-culture of